Sales rise 18.66% to Rs 1509.02 crore
Net profit of Alembic Pharmaceuticals declined 29.03% to Rs 121.92 crore in the quarter ended December 2022 as against Rs 171.79 crore during the previous quarter ended December 2021. Sales rose 18.66% to Rs 1509.02 crore in the quarter ended December 2022 as against Rs 1271.70 crore during the previous quarter ended December 2021. ParticularsQuarter EndedDec. 2022Dec. 2021% Var.Sales1509.021271.70 19 OPM %15.5819.01 -PBDT221.01256.72 -14 PBT154.50200.78 -23 NP121.92171.79 -29Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app